Human papillomavirus type 16 E5 (HPV-16 E5) is a highly hydrophobic membrane protein with weak-transforming activity, which is associated with ErbB4 receptor in HPV-16-infected cervical lesions. Presently, we investigated the transforming mechanisms of E5 involving ErbB4 signaling. Firstly, we report a role for ErbB4 (JM-b/CYT-1) receptor that activates c-jun gene expression and phosphorylating at Ser63 and Ser73 of the c-Jun protein in ligand-independent and Ras-c-jun NH 2 -terminal kinase-dependent pathway. Secondly, we show that HPV-16 E5 protein can form a complex with ErbB4 via binding to the extracellular and transmembrane domains of ErbB4 (JM-b/CYT-1). When co-expressing HPV-16 E5 and ErbB4 in cells, E5 can abrogate ErbB4-induced c-Jun protein expression and phosphorylation resulted in increasing cell proliferation compared to ErbB4-expressing cells. The interaction between of HPV-16 E5 and ErbB4 provides more insight into the mechanisms of HPV-16 E5 transformation induction.
Introduction
Human papillomavirus (HPV) type 16 E5 (HPV-16 E5) is a highly hydrophobic membrane protein with weak-transforming activity that has been linked with anchorage-independent growth of murine fibroblasts in vitro (DiMaio and Mattoon, 2001; zur Hausen, 2002; Tsai and Chen, 2003) . Bovine papillomavirus (BPV), the prototype of HPV, is well characterized; it is a hydrophobic membrane protein that can induce transformation of rodent and human fibroblasts (DiMaio and Mattoon, 2001) . BPV E5 forms complexes with various cellular proteins such as b-type platelet-derived growth factor receptor (b PDGF-R) as well as the 16 kDa subunit of the vacuolar H þ -ATPase located at the endosomal membrane. Like BPV E5, HPV-16 E5 has been identified to interact with a 16 kDa subunit of the vacuolar H þ -ATPase and epidermal growth factor receptor (EGFR); these interactions are important in cellular transformation (DiMaio and Mattoon, 2001; zur Hausen, 2002; Tsai and Chen, 2003; Genther Williams et al., 2005) . Binding of the 16 kDa subunit of the proton pump ATPase to HPV-16 E5 proteins leads to a reduction in the downregulation of EGFR and concomitant recycling of the receptor to the cell surface in E5-expressing cells (DiMaio and Mattoon, 2001; zur Hausen, 2002; Tsai and Chen, 2003) .
The ErbB family of growth factor receptor tyrosine kinases (RTKs) has four members: ErbB1 (EGFR), ErbB2, ErbB3 and ErbB4. ErbB4 is the most recently described member of the EGFR-like subfamily of RTKs (Plowman et al., 1993; Carpenter, 2003) . Ligands to ErbB4 are the neuregulins (NRG1-4), a group of alternatively spliced products of a single growth factor gene (Holmes et al., 1992; Wen et al., 1992; Falls et al., 1993; Marchionni et al., 1993) , and two EGF-like growth factors-betacellulin and heparin-binding EGFlike growth factor (HB-EGF), (Higashiyama et al., 1991; Shing et al., 1993; Beerli and Hynes, 1996; Riese et al., 1996; Graus-Porta et al., 1997; Elenius et al., 1997b) . As to ErbB4 receptor, there are four naturally occurring isoforms of ErbB4 generated by tissue-specific alterative splicing (Junttila et al., 2005) . They are characterized by variant extracellular juxtamembrane (JM) domains and intracellular cytoplasmic (CYT) domains and named ErbB4 JM-a/CYT-1, ErbB4 JMa/CYT-2, ErbB4 JM-b/CYT-1 and ErbB4 JM-b/CYT-2, respectively (Carpenter, 2003) . The ErbB4 isoform (JMa and JM-b) pairs that differ by insertion of 23 and 13 alternative amino acids in the extracellular JM region, respectively (Carpenter, 2003) . These two isoforms (JMa and JM-b) do not affect ligand binding, but do influence the sensitivity to proteolytic cleavage operated by tumor necrosis factor-a-converting enzyme (TACE) that cause the ErbB4 ectodomain shedding from the cell surface. It was concluded that JM-a isoform represents a cleavable form of ErbB4, whereas the JM-b form is uncleavable. A second isoform pair (CYT isoforms) contains sequence changes within the ErbB4 CYT domain and influences a receptor docking site for phosphatidyl inositol3-kinase (PI-3). The originally described ErbB4 sequence has a binding site for this signal transducer; however, this site is deleted in an isoform designated CYT-2. Therefore, the presence of the PI-3 kinase site is referred to CYT-1 isoform.
Following ligand binding, the ErbB4 receptor is activated by a process common to other ErbB receptors by a process of dimerization and autophosphorylation. To date, a few of these ErbB4 isoforms signaling molecules have been clearly identified. In this study, we investigate ErbB4 JM-b/CYT-1 isoform signaling. ErbB4 activation has been reportedly associated with diverse cellular responses, including proliferation, cell migration, differentiation and apoptosis (Weiss et al., 1997; Jones et al., 1999; Kainulainen et al., 2000; Long et al., 2003) . Previously, we found that HPV-16 E5 protein is significantly associated with ErbB4 receptor in HPV-16-infected cervical lesions (Chang et al., 2001) . Recent report demonstrated that Ras can induce ErbB4 JM-b/CYT-1 phosphorylation in ligand-independent pathway (Tal-Or et al., 2006) . HPV-E5 is a membrane protein that can induce c-jun gene expression via Rasdependent pathway (Tsao et al., 1995) . Therefore, we were interested in investigating the relationship between HPV-16 E5 and ErbB4 isoform JM-b/CYT-1. We investigate the transforming mechanisms of E5, including whether E5 can form a large multiprotein complex at the cell membrane to transmit signals to the nucleus via the cytoplasm. Presently, we report on immunoprecipitation assays that demonstrate the interaction of HPV 16 E5 with the EerbB4 JM-b/CYT-1 receptor. Confocal microscopy revealed E5 and ErbB4 JM-b/CYT-1 colocalization. We then generate a series of ErbB4 deletion mutants for binding affinity studies, and they demonstrate E5 binding to ErbB4 receptor occurs through extracellular and transmembrane domains of the latter. When HPV-16 E5 and ErbB4 JM-b/CYT-1 were co-transfected into cells, E5 inhibits ErbB4-induced c-Jun protein expression and phosphorylation, resulting in increasing cell proliferation compared to ErbB4-containing cells. Finally, in an intriguing finding, we report that ErbB4 JM-b/CYT-1 activated c-jun gene expression and phosphorylation at serine 63 and 73 of c-Jun via Ras-c-jun NH 2 -terminal kinase (JNK) signaling and is a ligand-independent pathway.
Results
Interaction between HPV-16 E5 protein and ErbB4 receptor Previously, we found that E5 protein is significantly associated with either the EGFR or ErbB4 receptors in HPV-16-infected lesions (Chang et al., 2001) . The HPV-16 E5 protein is reported to form complex with EGFR (Hwang et al., 1995) . Hence, we assessed whether complex formation occurred between the E5 protein and ErbB4 receptor. In the Introduction, we describe four natural isoforms of ErbB4, and here we use ErbB4 JM-b/CYT-1 isoform for assay. As shown in Figure 1A , cells containing ErbB4 JM-b/CYT-1 show no presence of 80 kDa cleavaged band as expected. Protein extracts of cells co-transfected with hemagglutinin (HA)-HPV-16 E5 and Myc-ErbB4 plasmids were immunoprecipitated with HA and Myc antibodies recognizing the E5 protein and ErbB4 JM-b/CYT-1 isoform, respectively, and the immunoprecipitates were examined by immunoblotting for the ErbB4 receptor, and vice versa. As shown in Figure 1B , the HA antibody immunoprecipitated with ErbB4 from cells co-expressing ErbB4 and E5 proteins ( Figure 1B , upper lane 3), but not from cells expressing ErbB4 in the absence of E5 protein ( Figure 1B , upper lane 4) and vice versa (panel B, lower lanes 7 and 8). To further locate the E5 and ErbB4 proteins, cells were transiently transfected with phosphorylated enhanced green fluorescent protein (pEGFP) C1-16E5 along with pDsRed C1-ErbB4 constructs. Forty-eight hours after transfection, fluorescent live proteins were monitored by confocal laser microscopy. As shown in Figure 1C , panel a, the red signal represents the localization of ErbB4 in cells transfected pDsRedC1-ErbB4 only. Panels b-d were cells co-transfected with pEGFP C1-16E5 and pDsRed C1-ErbB4; the green and red signals represent the localization of HPV-16 E5 (panel b) and ErbB4 (panel c), respectively; the orange signal represents the colocalization of E5 and ErbB4 (panel d), it seems that E5 protein can raft ErbB4. In sum, HPV-16 E5 protein was observed to colocalize with ErbB4.
Effect of HPV-16 E5 expression on ErbB4 receptor levels and phosphorylation BPV E5 protein can complex with PDGFR and stimulate receptor tyrosine phosphorylation (DiMaio and Mattoon, 2001; Lai et al., 2005) . To analyse the effect of ErbB4 receptor binding to HPV-16 E5 protein, cells were cotransfected with HPV-16 E5, ErbB4 and a GFP plasmid (the latter as an internal control). Twenty-four hours post-transfection, cells were deprived of serum starvation for a further 24 h, treated with HB-EGF for various times and cell lysates probed with antibodies to ErbB4, phosphotyrosine or GFP. As shown in Figure 1D , the binding of E5 and ErbB4 mildly delayed ErbB4 phosphorylation degradation, but not statistically significant difference from three independent experiments. ErbB4 receptor domain required for E5 protein binding encompasses the extracelluar and transmembrane domain of receptor Each ErbB receptor contains an extracellular ligandbinding domain of 600 to 630 amino acids, a single transmembrane a-helix, plus an intracellular domain of approximately 600 amino acids that includes the tyrosine kinase and regulatory sequences (Schlessinger and Ullrich, 1992; Mendrola et al., 2002) . The extracellular portion of ErbB receptor family consists of four domains: L1, CR1, L2 and CR2. L1 and L2 consist of b-solenoid or a-helix folds, and ligand binds between L1 and L2 of ErbB1 (Jorissen et al., 2003; Bouyain et al., 2005) . CR1 and CR2 contain disulfide bonds that facilitate dimerization with the other receptor.
In the subsequent experiments, we used mammalian two-hybrid Gal-4 transactivation system to examine which domains of ErbB4 are involved in the binding of E5 protein; 10 different ErbB4 deletion mutants based on the aforementioned ErbB1 category was generated ( Figure 2A and Table 1 ). cDNAs for these mutants, as well as the wild-type ErbB4, were inserted into the pcDNA3.1(À)/Myc-HisB-AD expression vector, which was designed to transcribe the Gal-4 activation domain (AD) fused genes from the cytomegalovirus enhancer promoter. Each fused gene encoded the Gal-4 ADs fusion protein, which contain nucleus localization signal leading the fused protein into nucleus for Gal-4 transactivation assay. To identify specific domains and amino acids in the ErbB4 receptor required for a productive interaction with the E5 protein, we examined a variety of mutant receptors in 293T cells by a mammalian two-hybrid assay. The 293T cells did not express endogenous ErbB4 receptor proposed to interact with the E5 protein, and so allowed analysis of ErbB4 receptor mutants in the absence of these confounding factors. Plasmids encoding all 11 receptor genes were individually used to co-transfect the BD-16E5 plasmid, which expressed a fusion protein of Gal DNA-binding domain into 293T cells along with pCH110 (b-galactosidase). The latter functioned as an internal control to normalize b-galactosidase activity. Relative binding activity of each fusion protein to HPV-16 E5 protein was compared to the activity of the AD-ErbB4, which expresses full-length ErbB4 receptor fused with a GaL4-AD (shown as 100%). As shown in Figure 2B , the ErbB4 receptor domains required for functional interaction with E5 encompassed the extracellular and transmembrane domains. Loss binding affinity to E5 of AD-R5, AD-R7, AD-R4, AD-R6, AD-F1, AD-F2, AD-F3 and AD-D1 receptors was owing to the absence of these regions of the ErbB4 protein. To determine expression levels of ErbB4 receptor in cells 
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S-L Chen et al co-transfected with E5 gene with different ErbB4 mutants, extracts were immunoblotted with the Gal4-AD antibody as described in Materials and methods. As shown in Figure 2C , the protein of ErbB4 full length and its mutants could be detected by arrows in all tests. ErbB4 receptor, in this study, was Gal4-AD tagged at 5 0 JM-b/CYT-1 isoform and its derived mutants. The 80 kDa protein of the cleavaged ErbB4 CYT domain could not be detected by immunoblotting with Gal4-AD antibody. Hence, some weak bands in Figure 2C , lanes R1, R5 and R4, were not the cleavaged CYT fragments. However, if the cleavage occurred, the 145 kDa of Gal4-AD-fused ectodomain fragment of ErbB4 should be presented in lanes ErbB4, R1 and R2 by the detection of Gal4-AD antibody. The results of Figure The backbone of vector is pcDNA3.1(À)Myc-HisB. b The backbone of vector is pcDNA3.1(À)Myc-HisB-AD.
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Effect of ErbB4 on c-Jun expression and phosphorylation
The transcriptional activity of c-Jun is increased by phosphorylation of the Ser63 and Ser73 residues in response to various stimuli, including ionizing radiation, ultraviolet light, cytokines and oxidative stress (Smeal et al., 1991 (Smeal et al., , 1994 Chen et al., 1998) . To investigate whether c-jun was activated in response to exposure of cells to ErbB4, we examined c-jun expression and phosphorylation on Ser63 and Ser73 in 293T cells incubated with HB-EGF for 30 min or without ligand. First, we constructed full-length ErbB4 (JM-b/ CYT-1 isoform) with a Myc epitope and a histidine tag at the C-terminal and designated as Myc-ErbB4 (as described in the Materials and methods and Table 1 ). Protein extracts from cells transfected 16-E5 and/or Myc-ErbB4 were prepared and subjected to immunoblot analysis with antibodies specific for total c-Jun or c-Jun phosphorylated on Ser63 or Ser73. The amount of c-Jun expression was increased and a biphasic pattern of c-Jun phosphorylation was apparent in ErbB4-expressing cells (Figure 3 , lanes 3 and 7). There was no apparent difference between the patterns obtained in presence and absence of HB-EGF treatment. It reveals that ErbB4 can activate c-jun gene expression and phosphorylate c-Jun on Ser63 and Ser73 independent of HB-EGF.
Owing to ErbB4-activating c-jun gene through ligandindependent pathway, the subsequent studies were omitted ligand treatment. To further measure the ErbB4 dose-effect on c-Jun expression and phosphorylation, cells were transfected with or without increasing amount of Myc-ErbB4 plasmids. After 48 h, cells were harvested and cell lysates were blotted with c-Jun, phospho-c-Jun (Ser63) or phospho-c-Jun (Ser73) antibodies. c-Jun phosphorylation status at both Ser positions was proportionally enhanced with increasing ErbB4 protein expression (Figure 4 ), indicating that phosphorylation was affected by ErbB4. The increase of c-Jun expression and phosphorylation correlated with the amount of ErbB4 JM-b/CYT-1 isoform. As we observed the induction of c-Jun and phosphorylation of c-Jun Ser63 as well as Ser73 by ErbB4, we were interested to investigate ErbB4 signaling to c-Jun. Cells transfected with Myc-ErbB4 plasmid were treated JNK, MAPkinase kinase (MEK), P38 and PI-3K inhibitor separately or co-transfected Ras dominant-negative mutant gene (Tsao et al., 1995) . As shown in Figure 4B , JNK inhibitor could block ErbB4-inducing c-Jun expression and Ser63 and Ser73 phosphorylation, Ras dominantnegative mutant gene decrease c-Jun protein expression and Ser63 phosphorylation but less effect on Ser73 phosphorylation; PI-3K, MEK and P38 inhibitors (data not shown) showed no effect on c-Jun expression and phosphorylation; indicating ErbB4 activates c-jun through Ras-JNK-dependent pathway. Moreover, we observed Myc-ErbB4 and ErbB4 deletion mutants (Myc-R2, Myc-R5 and Myc-F3; Table 1 ) on the effect of c-jun gene expression; the results showed that these mutants diminished ErbB4-eliciting c-Jun expression and phosphorylation ( Figure 5 , lanes 4-6). In sum, ErbB4 (JM-b/CYT-1) inducing c-Jun expression and phosphorylation at Ser63 as well as Ser73 are ligand independent and via Ras-JNK-dependent pathway.
ErbB4 inducing c-Jun expression and phosphorylation can be diminished by HPV-16 E5 by dose-dependent manner Our previous report illustrated that HPV-16 E5 can activate c-Jun expression (Tsao et al., 1996) . Here, as shown in Figure 1B and C, HPV-16 E5 could form complex with ErbB4; we then investigated the effect of c-Jun by E5 interaction with ErbB4. Figure 3 , lane 2, showed E5 alone could stimulate c-Jun expression and phosphorylation on Ser73 but not Ser63. In the presence of HB-EGF, c-Jun expression and phosphorylation on Ser73 by E5 were mildly increased but not significantly (Figure 3, lane 6) . However, when cells co-expressed E5 and ErbB4, E5 diminished ErbB4-inducing c-Jun expression and phosphorylation without ligand treatment (Figure 3, lanes 3 and 4) or ligand treatment (lanes 7 and 8). We can conclude that E5 diminished ErbB4-stimulating c-jun gene regardless of ligand treatment. To further confirm E5 demolishing ErbB4 signaling, we introduced varying amounts of HPV-16 E5 DNA into 293T-containing ErbB4 cells. As shown in Figure 6 , ErbB4 triggered c-Jun expression and phosphorylation at Ser63 and Ser73 were proportionally decreased by the amount of E5 gene expression. To quantify E5 expression, total RNAs were extracted and monitored by reverse transcription-polymerase chain reaction (RT-PCR), b-actin was used as a control (Figure 6, panel B) . In sum, the diminishing effect on ErbB4-inducing c-Jun expression and phosphorylation by HPV-16 E5 is dose dependent. 
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Evaluation of effects of HPV-16 E5 and ErbB4 complex on cell proliferation by MTT assay HPV-16 E5 is a transforming oncogene (DiMaio and Mattoon, 2001; zur Hausen, 2002; Tsai and Chen, 2003) . To analyse the biological effect of E5 and ErbB4 interaction, cells were transiently transfected with a plasmid containing HPV-16 E5, ErbB4, or a combination of HPV-16 E5 with ErbB4. After 24 h, cells were left untreated or were treated with HB-EGF, and a cell proliferation assay was conducted at various times after ligand stimulation. The results showed that HPV-16 E5 could cause cell proliferation and ErbB4 (JM-b/CYT-1) alone reduced cell growth compared to vector alone. The cell proliferation rate of HPV-16 E5 plus ErbB4 was higher than ErbB4 alone and lower than HPV-16 E5 alone ( Figure 7A and B). No discernable difference was apparent upon comparison with or without ligand treatment ( Figure 7A and B) . Taken together, there is a statistically significant difference by t-test in the cell growth rate between E5-and ErbB4-containing cells, as well as between E5 plus ErbB4-and ErbB4-expressing cells, regardless of ligand treatment. . In this study, we show that HPV-16 E5 protein can interact with ErbB4 JM-b/CYT-1 via binding to the extracellular and transmembrane domains. The interaction of these two proteins mildly extends phosphorylation on the ErbB4 receptor tyrosine in the presence of ligand but not significant. However, BPV E5, the prototype of HPV E5 is a very short transmembrane oncoprotein that specifically binds to PDGF-R (DiMaio and Mattoon, 2001; Lai et al., 2005) . The binding causes receptor activation via constitutive phosphorylation of a receptor tyrosine, and binding to downstream signaling substrates including PI-3 kinase-, phospholipase C-g-and ras guanine 5 0 -triphosphatase-activating protein (DiMaio and Mattoon, 2001 ). PDGF-R activation undoubtedly contributes to cellular transformation by BPV E5, as transforming E5 mutants have been described to be defective in PDGF-R binding that induces minimal PDGF-R phosphorylation (Sparkowski et al., 1996; Adduci and Schlegel, 1999) or dimerization (Adduci and Schlegel, 1999) . The domains of PDGF-R by BPV E5 protein binding also encompass the transmembrane and extracellular JM regions of the receptor (DiMaio and Mattoon, 2001) . Unlike BPV E5, dimerization of HPV-16 E5 has not been described. Additionally, the activation of ErbB4 phosphorylation by HPV-16 E5 is not significant (that is different from BPV ligandindependent E5 triggering of PDGF-R phosphorylation) (DiMaio and Mattoon, 2001) . The difference may primarily reside in E5 protein dimerization and cell tropism-related receptor binding of BPV to fibroblasts and HPV to epithelial cells.
Herein, we demonstrate for the first time that ErbB4 isoform JM-b/CYT-1-activating c-jun gene expression and inducing biphasic phosphorylation at Ser63 and Ser73 of c-Jun are ligand independent and Ras-JNKdependent pathway. Transcriptional activity of c-Jun is known to increase phosphorylation of Ser63 and Ser73 residues in response to various stimuli, including ionizing radiation, ultraviolet light, cytokines and oxidative stresses (Smeal et al., 1991 (Smeal et al., , 1994 Lee et al., 2001) . The phosphorylation of these c-Jun residues is essential for Ha-ras-inducing oncogenic activity (Smeal et al., 1991) , leading to increased activator protein-1 transcription activity and apoptosis (Derijard et al., 1994; Chen et al., 1998; Li et al., 2002) . The downstream nuclear signals transmitted by membrane ErbB4 receptor are unclear. So far, PI-3 kinase and signal transducer and activator of transcription (STAT)5 involving ErbB4 receptor signaling molecules are clearly demonstrated. Previous reports demonstrated that the activation of ErbB4 by either HB-EGF or neuregulin stimulates chemotaxis via PI-3 kinase dependent, and PI-3 kinase activation is only provoked by ErbB4 CYT-1 isoform containing PI-3 site, but not the CYT-2 isoform deleting this site (Kainulainen et al., 2000; Gambarotta et al., 2004) . The other signal is that ErbB4 in terminal differentiation of mammary epithelium can activate STAT5A, an important mediator of mammary differentiation (Jones et al., 1999; Clark et al., 2005) . Activated ErbB4 JM-a isoform can be cleaved within the juxtamembrane region by TACE, resulting in the shedding of a 120 kDa ErbB4 ectodomain and membrane association of the 80 kDa ErbB4 transmembrane region (4ICD) (Rio et al., 2000; Ni et al., 2001; Lee et al., 2002; Williams et al., 2004) that is the predominant form of nuclear ErbB4 isoform JM-a (Williams et al., 2004; Clark et al., 2005; Vidal et al., 2005) . In lactating mammary cells, 4ICD functions as a nuclear chaperone for STAT5A in the presence of ligand-heregulin b1; subsequently, the 4ICD-SATA5A complex translocates into the nucleus, targeting the lactation triggering b-casein promoter (Williams et al., 2004) . ErbB4 JM-a isoform is susceptibile to proteolytic cleavage operated by TACE but not JM-b isoform. Our study demonstrated that uncleavagable ErbB4 JM-b/CYT-1 convey a signal through Ras-JNK to increase c-jun expression and phosphorylation at Ser63 and Ser73. Further efforts to comprehensively identify the signal pathways of the various ErbB4 isoforms and ErbB4 JM-b/CYT-1-triggering c-Jun may lead to understanding the mechanisms of ErbB4-inducing biological effects.
Presently, ErbB4 isoform JM-b/CYT-1 expression decreased cell proliferation in 293T cells, which are human embryonic kidney epithelial cells immortalized with Simian 40 virus (SV40) large T-antigen (Graham et al., 1977) . There are four isoforms naturally occurring in different tissues; it is interesting to raise the issue of whether each ErbB4 isoform provokes different biological responses or different signal transductions are utilized. ErbB4 activation is reported to lead to cell proliferation, cell migration, differentiation and apoptosis (Weiss et al., 1997; Jones et al., 1999; Kainulainen et al., 2000; Long et al., 2003; Gambarotta et al., 2004) . 4ICD, ErbB4 JM-a receptor cleavaged fragment, induces apoptosis of malignant human breast cells by accumulating within mitochondria, resulting in mitochondrial permeabilization and cytochrome c release, the essential and committed step of mitochondrial dysfunction and apoptosis (Vidal et al., 2005) . In contrast, overexpression of 4ICD in estrogen receptorpositive breast cancer cells enhances cell proliferation and anchorage-independent growth (Junttila et al., 2005) . Clinical reports have indicated high expression levels of ErbB4 in neoplasias, including thyroid, breast, ovarian, endometrial and oral squamous cell cancer as well as medulloblastoma, ependymoma and osteosarcoma (Gullick, 2003) . However, ErbB4 expression is downregulated or lost in prostate (Lyne et al., 1997) , renal (Thomasson et al., 2004) and local pancreatic cancers (Graber et al., 1999) . In addition, ErbB4 also plays an important role in the embryonic development of heart, lung and nervous tissues (Plowman et al., 1993; Srinivasan et al., 1998; Gambarotta et al., 2004) . ErbB4 knockout mice exhibit cardiac and neural defects and die at early embryonic stage because of abnormal heart development (Gassmann et al., 1995; Jones et al., 1999; Golding et al., 2000) . In contrast to the expression of the other EGFR family members, expression of ErbB4 in breast and bladder cancers is associated with favorable E5 abrogated ErbB4-induced c-Jun phosphorylation S-L Chen et al prognosis (Bacus et al., 1994 (Bacus et al., , 1996 Knowlden et al., 1998; Memon et al., 2004 ) and a differentiating tumor phenotype (Srinivasan et al., 1998) . Thus, it has been proposed that ErbB4 may activate differentiation pathways in breast cancer cells and, thus, antagonize the oncogenic properties of other co-expressed EGFR family members (Jones et al., 1999; Carpenter, 2003) . Consistent with the present observations, the role of ErbB4 (JM-b/CYT-1) is skewed toward a differentiation response, rather than the proliferation response associated with the other three EGFR family members in mammary epithelium (Culouscou et al., 1995; Chen et al., 1996; Elenius et al., 1997a; Gambarotta et al., 2004) .
Previously, we found that HPV-16 E5 can induce c-jun gene expression that is associated with cell growth (Tsao et al., 1996) . Here, we further prove it. The amount of c-Jun expression and phosphorylation activated by E5 was less than ErbB4-induced, and it caused reversal effect on cell proliferation, as there was significant cell growth in E5-containing cells compared to ErbB4 cells (Po0.05). When E5 and ErbB4 were co-expressed, c-Jun-expression, c-Jun phosphorylation, and cell proliferation were intermediate between that observed when either gene was expressed alone. It can be explained the amount of c-Jun in E5 containing cells may be a maximum for cell growth, if higher than its threshold would cause cell death (Chen et al., 1998) . The mechanisms of c-jun dual roles for cell survival and apoptosis will be a further subject of study. Here, we demonstrate that HPV-16 E5 activates not only c-jun gene expression but also phosphorylation at Ser73, but not at Ser63, of c-Jun. Most intriguingly, either HPV-16E5 or ErbB4 (JM-b/CYT-1) can elicit the gene expression and phosphorylation of c-Jun. E5 can bind to N-terminal and transmembrane domain of ErbB4 (JM-b/CYT-1) that resulting HPV-16 E5 diminishes ErbB4-triggering of c-jun gene expression and phosphorylation in ligand-independent pathway. How the ErbB4 kinase activity leads to nucleus signals will be the further subject of study. Additionally, recent reports demonstrated one of ErbB4 binding protein Yes-associated protein (YAP) that is a WW domain-containing protein. YAP can form complex with the CYT region of full-length ErbB4 JM-a isoform at the membrane. After naturally occurring cleavage of ErbB4 JM-a, YAP still physically associates with ErbB4 CYT fragment (ErbB4-CTF), and YAPErbB4-CTF co-translocates into nucleus to enhance YAP-inducing transcriptional activity (Komuro et al., 2003; Aqeilan et al., 2005) . Hence, the interaction of ErbB4-binding domain transmitting signaling mechanism(s) involved will be the subject of further studies.
In conclusion, our findings provide the first description of ErbB4 JM-b/CYT-1-activating c-jun gene expression and phosphorylation at Ser63 and Ser73 via Ras-JNK-dependent pathway that cause decreasing cell proliferation. HPV-16 E5 alone can also induce c-jun gene expression and phosphorylation at Ser73 residue. Furthermore, HPV-16 E5 protein can form a complex with ErbB4 via binding to the extracellular and transmembrane domains of ErbB4. Co-expression of HPV-16 E5 and ErbB4 produces an E5-mediated diminishes of ErbB4-induced c-Jun protein expression and phosphorylation. Elucidation of the interaction between HPV-16 E5 and ErbB4 may shed more light on the mechanisms of HPV-16 E5-inducing transforming activity.
Materials and methods
HPV-16 E5-related plasmid constructions
The HA-16E5 plasmid, which is a pCEP4 (Invitrogen, Carlsbad, CA, USA)-based plasmid, was generated as described previously (Hsieh et al., 2000) . It contains an HPV-16 E5 open-reading frame (ORF) and the nucleotide sequence encoding the HA epitope, which is cloned in frame to the 5 0 end of E5 ORF. The HA1 16E5/pZip (S) plasmid was generated by cloning the HA epitope containing HPV-16 E5 cDNA fragment, which was cut from HA-16E5 plasmid by BamHI, into the pZipNeoSV40 (X) vector (a kind gift from Dr RC Mulligan) on the BamHI site. The pEGFP C1-16E5 plasmid used in fluorescence microscopy assay is a pEGFP C1 (BD Biosciences Clontech, Franklin Lakes, NJ, USA)-based plasmid that was generated by cloning the HPV-16 E5 cDNA fragment on the BamHI site of pEGFP C1 vector. The BD-16E5 plasmid, which expresses a fusion protein of GaL4 DNA-binding domain (GaL4-DBD) and HPV-16 E5, was generated by cloning the HPV-16 E5 cDNA fragment into the pcDNA3.1( þ )/BD vector on the EcoRI site. The pcDNA3.1( þ )/BD vector is a pcDNA3.1( þ ) (Invitrogen)-based plasmid that was generated by cloning a GAL4 DBD, from pAS2-1 vector (Clontech Matchmaker; Clontech Laboratories, Mountain View, CA, USA), on the EcoRI /HindIII site of the pcDNA3.1( þ ) vector. The other HPV-16 E5 expression plasmid, HisC-16E5, was constructed by cloning the HPV-16 E5 cDNA fragment into a pcDNA3.1/HisC vector (Invitrogen) at the EcoRI site.
ErbB4 and its mutant plasmid constructions
A full-length ErbB4 cDNA (kindly provided by Dr Hsing-Jen Kung) served as a template to generate full-length ErbB4 and truncated ErbB4 mutants by PCR-based approaches. The regions that were covered by the differently truncated ErbB4 fragments are summarized in Table 1 . The DNA fragments were cloned into the mammalian expression vector pcDNA3.1(À)/Myc-HisB (Invitrogen) at the EcoRV/NotI site. These plasmids expressing full-length or truncated ErbB4 with an Myc epitope and a histidine tags at the C-terminal were designated as Myc-ErbB4, Myc-R1, Myc-R2, Myc-R5, Myc-R7, Myc-R4, Myc-R6, Myc-F1, Myc-F2 and Myc-F3 (Table 1) . These ErbB4 fragments were also cloned into the pcDNA3.1(À)/Myc-HisB-AD vector at the EcoR V/Not I site. The pcDNA3.1(À)/Myc-HisB-AD vector is a pcDNA3.1(À)/ Myc-HisB-based plasmid and constructed by cloning a GAL4-AD at the HindIII site of the pcDNA3.1(À)/Myc-HisB vector. GAL4-AD was cut from the pACT2 vector (4739-5497 bp on pACT2, Clontech) by HindIII; it contains a SV40 T-antigen nuclear localization signal (5424-5478 bp on pACT2). The plasmids, which express full-length or truncated ErbB4 fused with a GaL4-AD at the N-terminal but without the Myc epitope and a histidine tags, were named AD-ErbB4 (fulllength), AD-R1, AD-R2, AD-R5, AD-R7, AD-R4, AD-R6, AD-F1, AD-F2 and AD-F3. The AD-D1 plasmid (amino acids 1-660 and 741-1308)-expressing full-length ErbB4 but without the transmembrane domain were constructed by cloning the F3 fragment into AD-R5 plasmid at the EcoRV site. The pDsRed C1-ErbB4 is a pDsRed C1 (BD Biosciences Clontech)-based plasmid and is generated by cloning the ErbB4 cDNA at the BglII site of the pDsRed C1 vector.
Cell culture and cell lines Human 293T cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) and antibiotics. The 293T/16E5 cells expressing HAtagged HPV-16 E5 were prepared by transfecting 293T cells with the HA1 16E5/pZip (S) plasmid encoding a neomycin resistance gene and an HPV-16 E5 gene containing a 5 0 HA epitope. The 293T/V cells generated by transfecting 293T cells with the pZipNeoSV40 (X) plasmid alone served as negative controls. These cells were selected using culture medium containing 500 mg/ml G418 (Geneticin; Calbiochem, San Diego, CA, USA) before confirmation of HPV-16 E5 protein expression. These two cell lines were maintained in culture medium with 100 mg/ml G418. JNK inhibitor 420119, MEK inhibitor PD98059, P38 inhibitor SB203580, PI-3K inhibitor LY294002 were purchased from Calbiochem (Merck). The working concentration was 20 mM.
Co-immunoprecipitation and Western blot analysis
We co-transfected 293T cells growing in a 100-mm diameter dish with 20 mg of HA-16E5 and/or 15 mg of Myc-ErbB4 constructs as indicated 24 h after seeding. The total amount of plasmid was adjusted with empty pcDNA3.1 vector to 35 mg for each 100-mm dish transfection using the calcium phosphate precipitation method. Forty-eight hours after transfection, cell extracts were harvested in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM ethylenediaminetetraacetic acid, 0.1% sodium dodecylsulfate (SDS), 1% Nonidet P-40, 0.5% Na-deoxycholate, 1 mM phenylmethylsulfonyl fluoride, aprotinin, leupeptin and pepstatin) and subjected to immunoprecipitation with antibodies against either HA (Clontech Laboratories) or Myc (Clontech Laboratories). The bound proteins were separated on 7.5 or 12.5% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred onto nitrocellulose filters. Nonspecific binding to the filters was blocked by a 1-h incubation in a buffer containing Tris-buffered saline with 0.1% Tween (TBS-T) (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% Tween-20) with 5% nonfat dry milk. The bound proteins were subsequently detected by successive 1-h incubations with HA antibody, or Myc antibody and a peroxidaseconjugated antimouse IgG antibody (Amersham Pharmacia Biotech, Piscataway, NJ, USA), both in TBS-T with 5% milk. Bound secondary antibody was visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech) and autoradiography.
Fluorescence microscopy assay Human 293T cells (3 Â 10 3 cells) on chamber slides (Nalge Nunc International, Naperville, IL, USA) were transfected with 1.5 mg of pEGFP C1-16E5 along with 1.5 mg of pDsRed C1-ErbB4 constructs using the FuGENE 6 transfection reagent (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's instructions. Forty-eight hours after transfection, cells were fixed with 4% paraformaldehyde in phosphate-buffered saline. Cells were washed, mounted and examined with a Nikon C1 confocal microscope with a Â 100 oil objective lens.
Western blot analysis of the expression and phosphorylation levels of proteins Cells growing in a 100-mm diameter dish were transfected with indicated plasmid DNAs by FuGENE 6 transfection reagent according to procedures recommended by the manufacturer. Forty-eight hours after transfection, cells were lysed using a lysis buffer supplied with phosphatase inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). For ligand treatment experiments, cells were serum starved in Dulbecco's modified Eagle's medium/0.1% FBS overnight before growth factor treatment. Cells were treated with HB-EGF (10 ng/ml) (Sigma) for 0, 15, 30 and 60 min as indicated and then lysed. The lysates were centrifuged, and 100 mg samples of total protein from the supernatants were separated on 7.5% or 10% SDS-PAGE gels. Western blot analysis processes were the same as described above. Antibodies to Gal4-TAD (Santa Cruz Biotechnology, Santa Cruz, CA, USA), ErbB4 (Santa Cruz Biotechnology), phosphotyrosine (Upstate Cell Signaling Solutions, NY, USA), GFP (Santa Cruz Biotechnology) and phosphoplus c-Jun (Cell Signaling Technology) were used in the blots.
Mammalian two-hybrid experiment
In 60-mm diameter dishes 293T cells were transiently cotransfected with 1.5 mg of reporter plasmid (G5E1B-LUC, a kind gift from Dr Guntram Suske, Philipps-Universita¨t Marburg, Germany), 2 mg of an internal control plasmid (pCH110, b-galactosidase; Amersham Biosciences), 3 mg of BD-16 E5 plasmid and 2 mg of Gal4-AD-fused ErbB4 mutant plasmid. Transient transfections were performed with FuGENE 6 (Roche Applied Science) according to the manufacturer's instructions. Forty-eight hours after transfection cells were harvested and the luciferase activities were determined using a Luminoskan TL Plus luminometer (Thermo Labsystems, Waltham, MA, USA). The b-galactosidase activity of cell lysates was determined and used to normalize luciferase activity. Relative binding activity of each ErbB4 mutant protein to HPV-16 E5 protein was compared to the activity of full-length ErbB4 receptor (shown as 100%).
Reverse transcription-polymerase chain reaction analysis HPV-16 E5 gene expression was measured by RT-PCR. The total RNA (20 mg) from each sample was reversely transcribed using M-murine leukemia virus reverse transcriptase (Invitrogen). One microliter of cDNA was amplified by PCR using the Expand High Fidelity PCR system (Roche Applied Science). The following forward and reverse primers were used: HPV-16 E5 (F): 5 0 -ATGACAAATCTTGATACTGCATCC-3 0 ; HPV-16 E5 (R): 5 0 -TTATGTAATTAAAAAGCGTGCATG-3 0 ; b-actin (F): 5 0 -ACCTTCAACACCCCAGCCATG-3 0 ; b-actin (R): 5 0 -CTGGAAGAGTGCCTCAGGGCA-3 0 . The reaction was run for 18 cycles at the annealing temperature of 601C. The primers amplified the 414 bp fragment of the b-actin, which was used to determine the relative amounts of RNA among samples, and the 249 bp fragment of the HPV-16 E5.
Cell proliferation assay
The Cell Titer 96 Aqueous One solution cell proliferation assay (Promega, Madison, WI, USA) is a quantitative colorimetric method for determining mammalian cell survival and proliferation. Cells were seeded at 2 Â 10 4 cells/well into 24-well plates 24 h before transfection. Cells were then transiently transfected with 0.6 mg of the indicated plasmid DNA per well using the FuGENE 6 transfection reagent. The total amount of plasmid transfected per dish was kept constant by adding empty vector to 1.2 mg DNA/well as needed. Twenty-four hours post-transfection, cells were treated with or without HB-EGF (10 ng/ml). Cell proliferation assay were performed before transfection (À24 h) and at 0, 24, 48 and 72 h after ligand stimulation. In the assay, 100 ml of the cell proliferation assay reagent was added to each well and the absorbance at 490 nm was read after incubation for 3 h at 371C using a Perkin-Elmer Lambda 40 UV/VIS spectrophotometer.
